Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Moderate to Severe Nail Psoriasis
NCT03897075Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of tildrakizumab in nail psoriasis and plaque psoriasis (2 arms), sponsored by Sun Pharma. Primary endpoint: Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at 28 weeks. Started May 2021; status: completed.
02
Drugs
tildrakizumab
03
Conditions
nail psoriasisplaque psoriasis
Beyond the preview
Go deeper on NCT03897075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897075.